Testing anakinra for treating kawasaki disease
Treatments studied
Part of Blood & lymphatic, Heart & circulation, Skin clinical trials.
This study tests whether anakinra, a medicine that calms inflammation, is just as good as the standard treatment for Kawasaki disease in children. The goal is to reduce fever and prevent heart problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be diagnosed with Kawasaki disease, which usually includes a fever lasting 5 or more days along with symptoms like red eyes, rash, swollen glands, or red lips and tongue.
- The fever should have started within the last 7 days at the time of enrollment.
- Your child must not have already developed heart complications (coronary artery aneurysms) from the disease.
- Your child must not have other serious conditions like Kawasaki shock syndrome or MIS-C.
- Your child must not have any prior heart disease.
- Your child must not be allergic to anakinra, IVIG, or aspirin.
- Your child must not be currently receiving IVIG, steroids, or other immune-suppressing drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two treatments—anakinra and IVIG—for children with Kawasaki disease who still have fever after their first standard IVIG treatment. It aims to find which option works better and is safer for “IVIG non-responders” who may be at risk for heart complications.
This trial tests whether adding a new medication (firsekibart) to the standard treatment for Kawasaki disease (immunoglobulin) works better than standard treatment alone. It aims to reduce the risk of heart problems and improve recovery.
This trial is testing a way to match children with Kawasaki disease to the best treatment. It looks at specific symptoms and fever duration to see if a child qualifies for the study, which may help doctors give the right treatment faster.
This study looks at children with Kawasaki disease, a condition that causes inflammation in blood vessels. The goal is to learn more about how it affects kids in Europe and North India.
This trial tests whether a cholesterol-lowering medication called atorvastatin can help children whose hearts were damaged by Kawasaki disease (a serious childhood illness that inflames blood vessels). The study may help reduce long-term heart complications.
This study uses heart imaging to better understand Kawasaki disease. It may help doctors assess heart health in affected children and teenagers.
Hear when a new Kawasaki Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.